Cargando…
Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells
Allograft rejection is an important issue post cardiac transplantation. In order to investigate the effect of combined treatment with simvastatin and rapamycin on allograft rejection, a cardiac transplantation rat model was employed in the present study. The survival time of rats following cardiac t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776515/ https://www.ncbi.nlm.nih.gov/pubmed/29434788 http://dx.doi.org/10.3892/etm.2017.5635 |
_version_ | 1783294092335120384 |
---|---|
author | Liu, Yingjie Sun, Lu Chen, Wei Chuai, Junbo Shang, Yu Zhang, Dongyang Fu, Bicheng Tian, Hai Jiang, Shulin |
author_facet | Liu, Yingjie Sun, Lu Chen, Wei Chuai, Junbo Shang, Yu Zhang, Dongyang Fu, Bicheng Tian, Hai Jiang, Shulin |
author_sort | Liu, Yingjie |
collection | PubMed |
description | Allograft rejection is an important issue post cardiac transplantation. In order to investigate the effect of combined treatment with simvastatin and rapamycin on allograft rejection, a cardiac transplantation rat model was employed in the present study. The survival time of rats following cardiac transplantation was recorded, while histopathological alterations were assessed by hematoxylin and eosin staining. The levels of transcription factors were measured by reverse transcription-quantitative polymerase chain reaction. In addition, the levels of CD4(+) interleukin (IL)-17(+) cells and CD4(+) forkhead box P3 (FOXP3)(+) cells in the allografts and CD4(+) T cells and CD8(+) T cells in the spleens were detected by flow cytometry. The results of the current study demonstrated that, following treatment with simvastatin and rapamycin, the survival time of model rats was prolonged, and the histopathological damage was attenuated. Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor γt (RORγt) level, increased FOXP3 level, reduced levels of CD4(+)IL-17(+), CD4(+) T and CD8(+) T cells, and increased level of CD4(+)FOXP3(+) cells. In conclusion, the current study observed that simvastatin and rapamycin performed a synergistic effect to reduce cardiac transplantation rejection. Thus, combined therapy of simvastatin and rapamycin may be a promising adjuvant therapy to reduce rejection post cardiac transplantation. |
format | Online Article Text |
id | pubmed-5776515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-57765152018-02-12 Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells Liu, Yingjie Sun, Lu Chen, Wei Chuai, Junbo Shang, Yu Zhang, Dongyang Fu, Bicheng Tian, Hai Jiang, Shulin Exp Ther Med Articles Allograft rejection is an important issue post cardiac transplantation. In order to investigate the effect of combined treatment with simvastatin and rapamycin on allograft rejection, a cardiac transplantation rat model was employed in the present study. The survival time of rats following cardiac transplantation was recorded, while histopathological alterations were assessed by hematoxylin and eosin staining. The levels of transcription factors were measured by reverse transcription-quantitative polymerase chain reaction. In addition, the levels of CD4(+) interleukin (IL)-17(+) cells and CD4(+) forkhead box P3 (FOXP3)(+) cells in the allografts and CD4(+) T cells and CD8(+) T cells in the spleens were detected by flow cytometry. The results of the current study demonstrated that, following treatment with simvastatin and rapamycin, the survival time of model rats was prolonged, and the histopathological damage was attenuated. Treatment with simvastatin and rapamycin also led to decreased retinoic acid receptor-related orphan receptor γt (RORγt) level, increased FOXP3 level, reduced levels of CD4(+)IL-17(+), CD4(+) T and CD8(+) T cells, and increased level of CD4(+)FOXP3(+) cells. In conclusion, the current study observed that simvastatin and rapamycin performed a synergistic effect to reduce cardiac transplantation rejection. Thus, combined therapy of simvastatin and rapamycin may be a promising adjuvant therapy to reduce rejection post cardiac transplantation. D.A. Spandidos 2018-02 2017-12-14 /pmc/articles/PMC5776515/ /pubmed/29434788 http://dx.doi.org/10.3892/etm.2017.5635 Text en Copyright: © Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Liu, Yingjie Sun, Lu Chen, Wei Chuai, Junbo Shang, Yu Zhang, Dongyang Fu, Bicheng Tian, Hai Jiang, Shulin Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells |
title | Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells |
title_full | Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells |
title_fullStr | Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells |
title_full_unstemmed | Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells |
title_short | Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells |
title_sort | combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of t helper 17 and regulatory t cells |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776515/ https://www.ncbi.nlm.nih.gov/pubmed/29434788 http://dx.doi.org/10.3892/etm.2017.5635 |
work_keys_str_mv | AT liuyingjie combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT sunlu combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT chenwei combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT chuaijunbo combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT shangyu combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT zhangdongyang combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT fubicheng combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT tianhai combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells AT jiangshulin combinedtreatmentwithsimvastatinandrapamycinattenuatescardiacallograftrejectionthroughtheregulationofthelper17andregulatorytcells |